117 related articles for article (PubMed ID: 7976632)
1. Effect of platelet-activating factor antagonist on brain injury in rats.
Tokutomi T; Sigemori M; Kikuchi T; Hirohata M
Acta Neurochir Suppl (Wien); 1994; 60():508-10. PubMed ID: 7976632
[TBL] [Abstract][Full Text] [Related]
2. Platelet-activating factor antagonist (TCV-309) attenuates the priming effects of bronchoalveolar macrophages in cerulein-induced pancreatitis rats.
Yamaguchi Y; Matsumura F; Liang J; Okabe K; Matsuda T; Ohshiro H; Ishihara K; Akizuki E; Yamada S; Ogawa M
Pancreas; 1999 May; 18(4):355-63. PubMed ID: 10231840
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of TCV-309--a potent PAF antagonist.
Terashita Z; Takatani M; Nishikawa K
J Lipid Mediat; 1992; 5(2):183-5. PubMed ID: 1445598
[TBL] [Abstract][Full Text] [Related]
4. Effect of platelet activating factor antagonist (TCV-309) on lung injury in dogs with experimentally endotoxin-induced shock.
Okano S; Tagawa M; Urakawa N
J Vet Med Sci; 1995 Aug; 57(4):751-3. PubMed ID: 8519912
[TBL] [Abstract][Full Text] [Related]
5. The roles of platelet-activating factor and endothelin-1 in renal damage after total hepatic ischemia and reperfusion.
Suzuki S; Serizawa A; Sakaguchi T; Tsuchiya Y; Kojima Y; Okamoto K; Kurachi K; Konno H; Fujise Y; Baba S; Nakamura S
Transplantation; 2000 Jun; 69(11):2267-73. PubMed ID: 10868624
[TBL] [Abstract][Full Text] [Related]
6. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
7. The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia.
Yin M; Buurman WA; Daemen JW; Kootstra G
Transplantation; 1996 May; 61(10):1443-6. PubMed ID: 8633367
[TBL] [Abstract][Full Text] [Related]
8. Platelet-activating factor in hepatic ischemia/reperfusion injury. The effects of a PAF antagonist combined with a prostaglandin I2 analogue.
Nishiyama R; Nakamura S; Suzuki S; Baba S
Transplantation; 1993 Jun; 55(6):1261-5. PubMed ID: 8516812
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation.
Kawamura M; Terashita Z; Imura Y; Shino A; Nishikawa K
Thromb Res; 1993 May; 70(4):281-93. PubMed ID: 8332959
[TBL] [Abstract][Full Text] [Related]
10. Platelet activating factor (PAF) antagonists: development of a highly potent PAF antagonist, TCV-309.
Takatani M; Maezaki N; Imura Y; Terashita Z; Nishikawa K; Tsushima S
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():943-6. PubMed ID: 1825438
[No Abstract] [Full Text] [Related]
11. Extended lung preservation with platelet-activating factor-antagonist TCV-309 in combination with prostaglandin E1.
Qayumi AK; English JE; Duncan S; Ansley DM; Pearson B; Nikbakht-Sangari M; Sammartino C; Fradet G
J Heart Lung Transplant; 1997 Sep; 16(9):946-55. PubMed ID: 9322146
[TBL] [Abstract][Full Text] [Related]
12. Role of platelet activating factor in ischaemia-reperfusion injury of isolated rabbit hearts: protective effect of a specific platelet activating factor antagonist, TCV-309.
Katoh S; Toyama J; Kodama I; Koike A; Abe T
Cardiovasc Res; 1993 Aug; 27(8):1430-4. PubMed ID: 8221795
[TBL] [Abstract][Full Text] [Related]
13. Platelet activating factor (PAF) inhibitor (TCV-309) reduces caerulein- and PAF-induced pancreatitis. A morphologic and functional study in the rat.
Tomaszewska R; Dembiński A; Warzecha Z; Banaś M; Konturek SJ; Stachura J
J Physiol Pharmacol; 1992 Dec; 43(4):345-52. PubMed ID: 1294265
[TBL] [Abstract][Full Text] [Related]
14. The platelet activating factor as a pivotal mediator of shock after liver ischemia.
Fukuoka T; Nakajima Y; Nakano H
Surg Today; 1995; 25(4):351-6. PubMed ID: 7633127
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effect of platelet-activating factor antagonist TCV-309 on renal ischemia-reperfusion injury.
Yin M; Kurvers HA; Buurman WA; Tangelder GJ; Booster MH; Daemen JH; Kondracki S; Kootstra G
Transplant Proc; 1995 Feb; 27(1):774-6. PubMed ID: 7879180
[No Abstract] [Full Text] [Related]
16. Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees.
Kuipers B; van der Poll T; Levi M; van Deventer SJ; ten Cate H; Imai Y; Hack CE; ten Cate JW
J Immunol; 1994 Mar; 152(5):2438-46. PubMed ID: 8133055
[TBL] [Abstract][Full Text] [Related]
17. Effects of a platelet activating factor antagonist on oedema formation following burns.
Ono I; Gunji H; Hasegawa T; Harada H; Kaneko F; Matsuzaki M
Burns; 1993 Jun; 19(3):202-7. PubMed ID: 8507364
[TBL] [Abstract][Full Text] [Related]
18. Role of platelet activating factor in cardiac dysfunction, apoptosis and nitric oxide synthase mRNA expression in the ischemic-reperfused rabbit heart.
Loucks EB; Godin DV; Walley KR; McManus BM; Rahimian R; Granville DJ; Hong JM; Aktary FM; Qayumi AK
Can J Cardiol; 2003 Mar; 19(3):267-74. PubMed ID: 12677282
[TBL] [Abstract][Full Text] [Related]
19. Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury.
Yin M; Kurvers HA; Buurman WA; Tangelder GJ; Tiebosch AT; Daemen JH; Kootstra G
Transplant Proc; 1995 Oct; 27(5):2844-6. PubMed ID: 7482939
[No Abstract] [Full Text] [Related]
20. The role of platelet-activating factor in regional myocardial ischemia-reperfusion injury.
Qayumi AK; English JC; Godin DV; Ansley DM; Loucks EB; Lee JU; Kim CW
Ann Thorac Surg; 1998 Jun; 65(6):1690-7. PubMed ID: 9647083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
